Prime Capital Market Limited (BOM:535514)

Orchard Therapeutics Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Cash & Equivalents	0.23	0.1	0.34	0.13	0.11
Trading Asset Securities	-	77.98	83.6	81.85	80.65
Cash & Short-Term Investments	0.23	78.07	83.94	81.98	80.76
Cash Growth	-99.71%	-6.99%	2.40%	1.50%	-5.20%
Accounts Receivable	47.2	0.02	-	0.2	0.2
Other Receivables	0.7	-	-	-	-
Receivables	77.08	27.34	33.52	35.87	16.17
Inventory	47.22	-	-	-	-
Other Current Assets	-	0.91	20.88	12.63	12.63
Total Current Assets	124.53	106.32	138.34	130.48	109.56
Long-Term Deferred Tax Assets	0.26	0.26	0.26	0.26	0.26
Long-Term Deferred Charges	-	-	-	0.09	0.18
Other Long-Term Assets	-	-0	-0	23.4	43.78
Total Assets	124.79	106.58	138.6	154.23	153.77
Accounts Payable	0.28	5.47	38.79	51.37	51.37
Accrued Expenses	0.36	2.35	1.61	2.69	1.99
Current Income Taxes Payable	2.18	0.3	0.03	-	-
Other Current Liabilities	-	0.11	0.07	0.1	0.07
Total Current Liabilities	2.83	8.23	40.5	54.16	53.43
Long-Term Debt	2	2	2	2	2
Long-Term Unearned Revenue	18.84	1.19	1.08	3.56	3.36
Other Long-Term Liabilities	-	-	-0	-	-
Total Liabilities	23.67	11.42	43.57	59.72	58.78
Common Stock	100	100	100	100	100
Retained Earnings	1.12	-4.84	-4.97	-5.49	-5.01
Comprehensive Income & Other	-	-	-	-0.01	-
Shareholders' Equity	101.12	95.16	95.03	94.5	94.99
Total Liabilities & Equity	124.79	106.58	138.6	154.23	153.77
Total Debt	2	2	2	2	2
Net Cash (Debt)	-1.77	76.07	81.94	79.98	78.76
Net Cash Growth	-	-7.16%	2.46%	1.54%	-5.32%
Net Cash Per Share	-0.18	7.61	8.19	8.00	7.88
Filing Date Shares Outstanding	10	10	10	10	10
Total Common Shares Outstanding	10	10	10	10	10
Working Capital	121.7	98.09	97.84	76.31	56.13
Book Value Per Share	10.11	9.52	9.50	9.45	9.50
Tangible Book Value	101.12	95.16	95.03	94.5	94.99
Tangible Book Value Per Share	10.11	9.52	9.50	9.45	9.50

Source: S&P Global Market Intelligence. Standard template. Financial Sources.